A new discovery by scientists has revealed that a chemical compound that amputates energy supply to glioblastoma cells resulting in self-destruction. Glioblastoma refers to a terminal form of brain cancer. These tumors surface from the supportive, sticky brain tissues that gets a sufficient supply of blood. Since the destructive cells reproduce very fast, there are hitches and difficulties in treating this type of cancer.
This destructive cancer has an average survival rate of 10 to 12 months. As stated by some studies, the five-year survival rate is lower than 10%. A newly carried research has promising results. A worldwide team of scientists’ reports have discovered a way of ending the generative rate of these cancer cells. Referred to as KHS101, this new artificial chemical compound amputates energy source to the cancer cells. The study was led by Heiko Wurdak from the University of Leeds, UK and published in the periodical of Science Translational Medicine.
The synthetic chemical compound, has the ability to cut the malignant tumor growth in half. Experiments conducted in the laboratory revealed that this compound interrupts the cancer cells’ mitochondria. Mitochondria are the minute organelles in the body cells that convert nutrients into energy. This, in return, causes the cancer cells to self-destruct. This surprised the scientists who initially thought that the synthetic compound would slow down the growth of glioblastoma.
Another thing that these scientists sought to comprehend is whether or not KHS101could infiltrate the blood-brain obstacle. This is the barrier between the capillaries and the cells, as well as additional components that constitute the brain tissue. The barrier is significant for it protects the human body from pathogens like viruses and bacteria. Any attempt by specialists to administer drugs might be an obstacle. Thus, to examine the effects, Wurdak and his team transferred the human cancer cells into a mouse.
Findings from the research above showed that mice treated with KHS101 revealed a 50% shrinkage in their tumors. This was an indication that the compound could certainly cross the blood-brain blockade. The mice treated with KHS101 stayed alive with the tissues around the tumors unaffected. KHS101 exhibited the prospect of treating all the unalike chromosomal disparities of cells within the cancers. According to Wurdak, they hope that the drug developers will start examining the uses of KHS101 to assist in clinical life-extensions. A brain tumor professional, Prof. Richard Gilbertson, of Cancer Research UK – a charitable institute welcomed the findings. He said they offer a potential cure. In 2015, 23,000 adults were identified with brain tumors in the US, with 50% being glioblastomas.